- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06785012
Badanie mające na celu zbadanie skuteczności JNJ-89495120 w leczeniu dużych zaburzeń depresyjnych (Moonlight-1)
Randomizowane, podwójnie ślepe, wieloośrodkowe, kontrolowane placebo badanie weryfikujące koncepcję, mające na celu ocenę skuteczności, bezpieczeństwa i tolerancji preparatu JNJ-89495120 w monoterapii u dorosłych pacjentów z poważnymi zaburzeniami depresyjnymi (MDD)
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Alabama
-
Huntsville, Alabama, Stany Zjednoczone, 35801
- UAB Huntsville Regional Medical Campus
-
-
Arizona
-
Chandler, Arizona, Stany Zjednoczone, 85224
- Chandler Clinical Trials
-
Phoenix, Arizona, Stany Zjednoczone, 85012
- IMA Clinical Research PC Phoenix
-
Tucson, Arizona, Stany Zjednoczone, 85724
- University of Arizona
-
Tucson, Arizona, Stany Zjednoczone, 85704
- Noble Clinical Research
-
-
California
-
Bellflower, California, Stany Zjednoczone, 90706
- CI Trials
-
Encino, California, Stany Zjednoczone, 91316
- Wake Research PRI Encino
-
Garden Grove, California, Stany Zjednoczone, 92844
- National Institute Of Clinical Research
-
Newport Beach, California, Stany Zjednoczone, 92660
- WR-Newport Beach
-
Orange, California, Stany Zjednoczone, 92866
- ATP Clinical Research
-
Redlands, California, Stany Zjednoczone, 92374
- Anderson Clinical Research
-
San Diego, California, Stany Zjednoczone, 92103
- Artemis Institute for Clinical Research
-
San Jose, California, Stany Zjednoczone, 95124
- Lumos Clinical Research Center LLC
-
Santa Ana, California, Stany Zjednoczone, 92705
- Syrentis Clinical Research
-
Temecula, California, Stany Zjednoczone, 92591
- Inland Psychiatric Medical Group Inc
-
Walnut Creek, California, Stany Zjednoczone, 94596
- Sunwise Clinical Research
-
-
Colorado
-
Denver, Colorado, Stany Zjednoczone, 80209
- Mountain View Clinical Research
-
-
Florida
-
Fort Myers, Florida, Stany Zjednoczone, 33912
- Gulfcoast Medical Research Center
-
Hollywood, Florida, Stany Zjednoczone, 33021
- The Medici Medical Research
-
Homestead, Florida, Stany Zjednoczone, 33030
- Advanced Research Institute of Miami
-
Maitland, Florida, Stany Zjednoczone, 32751
- K2 Medical Research
-
Miami, Florida, Stany Zjednoczone, 33126
- Pharmax Research Clinic Inc
-
Miami, Florida, Stany Zjednoczone, 33135
- Wellness Research Center
-
Pembroke Pines, Florida, Stany Zjednoczone, 33024
- Best Choice Medical and Research Service
-
Tampa, Florida, Stany Zjednoczone, 33629
- Interventional Psychiatry of Tampa Bay
-
West Palm Beach, Florida, Stany Zjednoczone, 33407
- Health Synergy Clinical Research
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30328
- Synexus Clinical Research US Inc
-
Decatur, Georgia, Stany Zjednoczone, 30030
- iResearch Atlanta LLC
-
Snellville, Georgia, Stany Zjednoczone, 30078
- Accelerated Clinical Research Group LLC
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60637
- University of Chicago Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone, 46202
- Indiana University IU Health
-
-
Louisiana
-
New Orleans, Louisiana, Stany Zjednoczone, 70115
- DelRicht Research
-
-
Maryland
-
Gaithersburg, Maryland, Stany Zjednoczone, 20877
- CBH Health
-
-
Massachusetts
-
Worcester, Massachusetts, Stany Zjednoczone, 01655
- University of Massachusetts Medical School
-
-
New York
-
Brooklyn, New York, Stany Zjednoczone, 11229
- Integrative Clinical Trials LLC
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45219
- University of Cincinnati
-
Cincinnati, Ohio, Stany Zjednoczone, 45215
- Patient Priority Clinical Sites LLC
-
Columbus, Ohio, Stany Zjednoczone, 43210
- OSU Department of Psychiatry and Behavioral Health
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73116
- Paradigm Research Professionals, LLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
- University of Pennsylvania
-
-
South Carolina
-
North Charleston, South Carolina, Stany Zjednoczone, 29405
- Coastal Carolina Research Center
-
-
Texas
-
McKinney, Texas, Stany Zjednoczone, 75071
- Revival Research Institute LLC
-
-
Utah
-
Clinton, Utah, Stany Zjednoczone, 84015
- Alpine Research Organization
-
-
Washington
-
Everett, Washington, Stany Zjednoczone, 98201
- Core Clinical Research
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using diagnostic and statistical manual of mental disorders (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MINI)
- Participant had to have at least one previous major depressive disorder (MDD) episode prior to their current episode
- Were first diagnosed with depression before the age of 55
- Are in a current episode of depression: Episode length must be at least 2 months but not longer than 24 months
- Have taken 0, 1, or 2 treatments for depression in your current episode
- Body mass index (BMI) within the range 18 to 35 kilograms per square meter (kg/m^2) at screening
Exclusion Criteria:
- Treatment with vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), or ketamine/esketamine within the current or past major depressive episodes
- Current or past DSM-5 diagnosis of bipolar disorder, psychotic disorders, borderline personality disorder, antisocial personality disorder, or current obsessive-compulsive disorder
- Post-traumatic stress disorder within the past three years of screening
- Dementia, any dementing disease, intellectual disability, or neurocognitive disorder
- History of Alcohol and Substance use disorders within 6 months of screening, with the exclusion of nicotine, caffeine, and mild cannabis use disorder, according to the MINI and Clinical Assessment
- Known allergies, hypersensitivity, or intolerance to JNJ-89495120 or its excipients
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Arm 1: JNJ-89495120 Dose A
Participants will receive JNJ-89495120 dose A during the double-blind (DB) treatment phase in Period 1 and Period 2 of the study. |
JNJ-89495120 will be administered. |
|
Eksperymentalny: Arm 2: JNJ-89495120 Dose A and Dose B
Participants will receive JNJ-89495120 dose A in Period 1 followed by JNJ-89495120 dose B in Period 2 during the DB treatment phase of the study. |
JNJ-89495120 will be administered. |
|
Komparator placebo: Arm 3: Placebo Group
Participants will receive placebo matched to JNJ-89495120 during the DB treatment phase in Period 1 and Period 2 of the study. |
Placebo will be administered. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Day 5
Ramy czasowe: Baseline up to Day 5
|
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. |
Baseline up to Day 5
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change from Baseline in MADRS Total Score to Day 2
Ramy czasowe: Baseline up to Day 2
|
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. |
Baseline up to Day 2
|
|
Change from Baseline in Clinician Global Impression-Severity (CGI-S) Scale Score to Days 2 and 5
Ramy czasowe: Baseline up to Day 2 and Day 5
|
The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Participant is assessed on severity of illness at the time of rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. Higher score indicating greater severity. |
Baseline up to Day 2 and Day 5
|
|
Change from Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score to Day 5
Ramy czasowe: Baseline up to Day 5
|
The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item is rated by the participant according to a 5-point Likert scale, where 0 denotes "Not at all" or "Never" and 4 denotes "Extremely" or "Always". Before summing the items to create a total score, item 11 and item 12 are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items, which range from 0 to 60. Higher score indicates more severe depressive symptomatology. |
Baseline up to Day 5
|
|
Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Scale Score to Day 5
Ramy czasowe: Baseline up to Day 5
|
The GAD-7 scale is a self-administered questionnaire designed to measure anxiety. GAD-7 has seven items, which measure frequency of various signs of GAD using a 4-point Likert scale (where, Not at all = 0, Several days = 1, More than half the days = 2, and Nearly every day = 3). The total score ranges from 0 to 21 with increasing scores indicative of greater severity of symptoms of anxiety. Severity of anxiety on the GAD-7 is rated as follows: none (0-4), mild (5-9), moderate (10-14) and severe (15-21). |
Baseline up to Day 5
|
|
Number of Participants with Adverse Events (AEs)
Ramy czasowe: Up to approximately 18 weeks
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. |
Up to approximately 18 weeks
|
|
Number of Participants with Abnormalities in Vital Signs Parameters
Ramy czasowe: Up to approximately 18 weeks
|
Participants with abnormalities in vital signs (supine blood pressure, pulse/heart rate, respiratory rate, oral temperature) parameters will be reported. |
Up to approximately 18 weeks
|
|
Number of Participants with 12-Lead Electrocardiogram (ECG) Abnormalities
Ramy czasowe: Up to approximately 18 weeks
|
Participants with 12-lead ECG abnormalities will be reported. |
Up to approximately 18 weeks
|
|
Number of Participants With Abnormalities in Laboratory Parameters
Ramy czasowe: Up to approximately 18 weeks
|
Participants with abnormalities in clinical laboratory parameters (hematology and serum chemistry) will be reported. |
Up to approximately 18 weeks
|
|
Number of Participants Reporting Changes in Weight/Body Mass Index (BMI)
Ramy czasowe: Up to approximately 18 weeks
|
Participants with changes in weight/BMI will be reported. |
Up to approximately 18 weeks
|
|
Suicidal Ideation Assessment Using Columbia Suicide Severity Rating Scale (C-SSRS) Score
Ramy czasowe: Up to approximately 18 weeks
|
The C-SSRS scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline. |
Up to approximately 18 weeks
|
|
Change from Baseline in Cognitive Functioning Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)
Ramy czasowe: From Baseline up to 4 weeks
|
The HVLT-R, a measure of verbal learning and memory, is a 12-item word list recall test. Administration includes 3 learning trials, a delayed recall (20-minute) trial, and a 24-word recognition list (including 12 target and 12 foil words). The test administrator reads instructions and word lists aloud, and records words recalled/recognized by the participant. Three learning trials are combined to calculate a total recall score learning, delayed recall, and recognition trials. |
From Baseline up to 4 weeks
|
|
Change from Baseline in Cognitive Functioning Measured by the Digit Symbol Substitution Test (DSST)
Ramy czasowe: From Baseline up to 4 weeks
|
The DSST is recognized as covering all of the cognitive performance aspects: speed of processing, executive functioning, and attention. The DSST measures attention, working memory, sustained visual attention and psychomotor speed. Participants are given a table that pairs digits and symbols, and asked to decipher a code using the table, completing as many as possible in 90 seconds. |
From Baseline up to 4 weeks
|
|
Plasma Concentrations of JNJ-89495120
Ramy czasowe: Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13
|
Plasma concentrations of JNJ-89495120 will be reported. |
Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13
|
Współpracownicy i badacze
Śledczy
- Dyrektor Studium: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 89495120MDD2001
- 89495120MDD2001 (Inny identyfikator: Janssen Research & Development, LLC)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .